A field to watch

What podcasts are saying about GLP-1 drugs.

Start my GLP-1 drugs briefing →Shared shows free
custom feeds from $8.99/mo
GLP-1 drugsNovember 11–14, 2026

Two shows, one fight: are these drugs costing people their muscle?

“there is an inordinate amount of muscle loss that goes along with the weight loss.”

“We're frequently treating lean mass and skeletal muscle mass as though they're interchangeable. They're not.”

“I think we need to stop making the leap from lean mass loss to muscle damage every time a new study comes out.”

Read the story

A quieter stretch, and two shows arguing about the same thing. Dr. Ken Berry, a family physician, repeated the warning on his own show: for patients who keep their old diet, there is “an inordinate amount of muscle loss that goes along with the weight loss.”

Two days later the host of Weight & Measure walked through a new study comparing tirzepatide and semaglutide and said the alarm rests on a mix-up between lean mass and muscle. The gap between the two drugs looked like 2.1 percentage points, and shrank to about 0.1 once total weight loss was accounted for.

Both say muscle is worth protecting. They split on whether the drug or the measurement is the problem.

119,000

podcasts searched for GLP-1 drugs, before every briefing.

Hard ForkThe DailyOdd LotsAcquiredAll-InPlanet MoneyLex Fridman PodcastHuberman LabThe JournalDecoder with Nilay PatelPivotThe Ezra Klein ShowDwarkesh PodcastInvest Like the BestSquawk on the StreetGoldman Sachs ExchangesHard ForkThe DailyOdd LotsAcquiredAll-InPlanet MoneyLex Fridman PodcastHuberman LabThe JournalDecoder with Nilay PatelPivotThe Ezra Klein ShowDwarkesh PodcastInvest Like the BestSquawk on the StreetGoldman Sachs Exchanges
Masters of ScaleDr. Ken BerryWeight & MeasureWSJ Your Money BriefingThe CircuitBloomberg TalksUnhedged80,000 Hours PodcastEquityThe AI Daily BriefSchwab NetworkRide the LightningElectrifiedLimitlessSpecial BriefingOn Investors’ MindsSNIA Experts on DataGlobal Research UnlockedMasters of ScaleDr. Ken BerryWeight & MeasureWSJ Your Money BriefingThe CircuitBloomberg TalksUnhedged80,000 Hours PodcastEquityThe AI Daily BriefSchwab NetworkRide the LightningElectrifiedLimitlessSpecial BriefingOn Investors’ MindsSNIA Experts on DataGlobal Research Unlocked

More to hear.

Anthropic

Everyone has a number for Anthropic. Nobody agrees what it’s worth.

Start my Anthropic briefing →
Tesla

The Cybertruck is ending. The shows are arguing about what replaces it.

Start my Tesla briefing →
The Fed and interest rates

Nobody is arguing about whether the Fed hikes in December. They’re arguing about how much.

Start my The Fed and interest rates briefing →
AI data centers

Seven in ten Americans don’t want one nearby. Investors are told to expect 30%.

Start my AI data centers briefing →